Page last updated: 2024-12-04

isopentenyl pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1195
CHEMBL ID356362
CHEBI ID16584
SCHEMBL ID125521
MeSH IDM0045988

Synonyms (43)

Synonym
gtpl3048
IPP ,
3-methylbut-3-en-1-yl trihydrogen diphosphate
CHEBI:16584 ,
3-methylbut-3-enyl phosphono hydrogen phosphate
3-methyl-3-butenyl pyrophosphate
mono(3-methyl-3-butenyl) diphosphate
ippp
isopentenyl pyrophosphate
diphosphoric acid mono(3-methyl-3-butenyl) ester
delta-3-isopentenyl pyrophosphate
isopentenyl-diphosphate
LMPR01010008
delta3-isopentenyl pyrophosphate
[14c]isopentenyl diphosphate
({hydroxy[(3-methylbut-3-en-1-yl)oxy]phosphoryl}oxy)phosphonic acid
[14c]ipp
bdbm25257
C00129
delta3-methyl-3-butenyl diphosphate
358-71-4
delta3-isopentenyl diphosphate
isopentenyl diphosphate
DB04714
3-methylbut-3-enyl trihydrogen diphosphate
isopentenyl-pp
delta(3)-isopentenyl-pp
CHEMBL356362
isopentenylpyrophosphate
delta-3-isopentenyl pyrophosphat
unii-lsc8849m7b
lsc8849m7b ,
EPITOPE ID:194668
SCHEMBL125521
diphosphoric acid, p-(3-methyl-3-buten-1-yl) ester
NUHSROFQTUXZQQ-UHFFFAOYSA-N
Q417403
diphosphoric acid,p-(3-methyl-3-buten-1-yl) ester
isopentenyl pyrophosphate ammonium salt
DTXSID80861893
isopentenyl pyrophosphate ammonium 200
3-buten-1-ol, 3-methyl-, pyrophosphate
diphosphoric acid, mono(3-methyl-3-butenyl) ester

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" However, bisphosphonates exhibit a high affinity for bone mineral, which reduces their bioavailability for tumor cells."( Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Clézardin, P; Gineyts, E; Melodelima, D; Ngo, J; Roux, JP; Tardoski, S, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13
" They are observed exclusively in patients starting ALN or RSN treatment with once weekly dosage regimens."( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
phosphoantigenAny antigen that is a phosphorylated microbial metabolite which activates an immune response in humans.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antigenAny substance that stimulates an immune response in the body, such as through antibody production or by presentation to a T-cell receptor after binding to a major histocompability complex (MHC).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prenol phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (75)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Metabolism of vitamins and cofactors146155
Metabolism of cofactors1947
Ubiquinol biosynthesis824
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Secondary Metabolites: Methylerythritol Phosphate and Polyisoprenoid Biosynthesis1121
Secondary Metabolites: Isoprenoid Biosynthesis (Nonmevalonate Pathway)818
Secondary Metabolites: Ubiquinol Biosynthesis922
Metabolism of proteins1058144
Secondary Metabolites: Ubiquinol Biosynthesis 2923
Terpenoid Backbone Biosynthesis1322
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
Synthesis of Dolichyl-phosphate617
Epoxysqualene Biosynthesis612
Plastoquinol-9 Biosynthesis616
Farnesene Biosynthesis68
Disease1278231
Diseases of metabolism69121
Diseases of glycosylation2243
Diseases associated with glycosylation precursor biosynthesis621
Defective DHDDS causes RP5922
Steroids metabolism ( Steroids metabolism )1627
Dimethylallyl diphosphate = Isopentenyl diphosphate ( Steroids metabolism )22
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Cholesterol Biosynthesis and Metabolism2248
Mevalonate Pathway1126
MEP/DOXP Pathway819
Cholesterol biosynthesis pathway in hepatocytes1137
Ergosterol biosynthesis332
superpathway of sterol biosynthesis050
trans, trans-farnesyl diphosphate biosynthesis I05
ubiquinone (coenzyme Q) biosynthesis026
Isoprenoid precursor biosynthesis in Pf apicoplasts012
Geranylgeranyldiphosphate biosynthesis II (plastidic)03
Methylerythritol phosphate pathway07
Biochemical pathways: part I0466
GPP biosynthesis04
DXP pathway520
FPP biosynthesis05
GGPP biosynthesis II (plastidic)06
MVA pathway116
Polyisoprenoid biosynthesis06

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Butyrophilin subfamily 3 member A1Homo sapiens (human)IC50 (µMol)513.00004.56007.10009.6400AID1569596
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Butyrophilin subfamily 3 member A1Homo sapiens (human)EC50 (µMol)36.00000.00010.47193.0600AID1569584; AID1569591; AID1676487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
positive regulation of cytokine productionButyrophilin subfamily 3 member A1Homo sapiens (human)
adaptive immune responseButyrophilin subfamily 3 member A1Homo sapiens (human)
positive regulation of type II interferon productionButyrophilin subfamily 3 member A1Homo sapiens (human)
activated T cell proliferationButyrophilin subfamily 3 member A1Homo sapiens (human)
T cell receptor signaling pathwayButyrophilin subfamily 3 member A1Homo sapiens (human)
regulation of cytokine productionButyrophilin subfamily 3 member A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
protein bindingButyrophilin subfamily 3 member A1Homo sapiens (human)
signaling receptor bindingButyrophilin subfamily 3 member A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneButyrophilin subfamily 3 member A1Homo sapiens (human)
external side of plasma membraneButyrophilin subfamily 3 member A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID221770Effective concentration to activate gammadelta T cells2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens.
AID159563Relative yield of the product (FPP) derived from the compound with GPP in the enzymatic reaction catalyzed by FPP synthase from porcine liver1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID40493Relative yield of the product (FPP) derived from the compound with GPP in the enzymatic reaction catalyzed by FPP synthase from Bacillus stearothermophilus1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID216550Mean effective concentration of compound was determined in stimulating Vgamma9 / Vdelta2 T cell2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.
AID1676487Binding affinity to BTN3A1 in human PBMC-derived Vgamma9/Vdelta2 T cells
AID390270Stimulation of human Vgamma9Vdelta2 T lymphocytes assessed as gamma delta expansion factor after 7 days2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.
AID216549Effective concentration range of compound was determined in stimulating Vgamma9 / Vdelta2 T cell2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.
AID1829588Inhibition of human SHIP2 catalytic domain (419 to 832 residues) phosphatase activity assessed as phosphate release using Ins(1,3,4,5)P4 as substrate at 1 mM incubated for 20 mins measured using microplate reader2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.
AID375410Stability in presence alkaline phosphatase after 20 mins by HPLC-MS analysis2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators.
AID40492Relative yield of the product (FPP) derived from the compound with DMAPP in the enzymatic reaction catalyzed by FPP synthase from Bacillus stearothermophilus1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID38010Relative yield of the product (FPP) derived from the compound with GPP in the enzymatic reaction catalyzed by FPP synthase from avian liver1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID1569596Displacement of GDP-BODIPY from C-terminal 6His-tagged BTN3A1 B30.2 domain (unknown origin) expressed in Escherichia coli BL21 (DE) measured after 60 mins by fluorescence polarization assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Probing the Ligand-Binding Pocket of BTN3A1.
AID375412Stability in presence alkaline phosphatase after 60 mins by HPLC-MS analysis2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators.
AID216548Activity against isopentenyl pyrophosphate (IPP) in Vgamma9 / Vdelta2 T cell2003Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7
Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.
AID1163703Inhibition of Populus trichocarpa DXS2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Development of inhibitors of the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway enzymes as potential anti-infective agents.
AID375411Stability in presence alkaline phosphatase after 30 mins by HPLC-MS analysis2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators.
AID1569591Activation of BTN3A1 in human PBMC-derived Vgamma9/Vdelta2 T cells assessed as induction of IL2-stimulated IFNgamma production measured after 48 hrs by ELISA2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Probing the Ligand-Binding Pocket of BTN3A1.
AID1569584Activation of BTN3A1 in human PBMC-derived Vgamma9/Vdelta2 T cells assessed as induction of IL2-stimulated cell proliferation by measuring increase in CD3+ cells preincubated for 3 days followed by 11 days incubation post compound washout and subsequent I2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Probing the Ligand-Binding Pocket of BTN3A1.
AID375409Stability in presence of alkaline phosphatase2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators.
AID375408Immunostimulatory activity in human Vgamma9/Vdelta2 T cells assessed as TNFalpha production after 12 hrs by ELISA2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators.
AID159562Relative yield of the product (FPP) derived from the compound with DMAPP in the enzymatic reaction catalyzed by FPP synthase from porcine liver1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID317317Agonist activity at human Vgamma9Vdelta2 receptor expressed in T cells assessed as stimulation of TNFalpha release by ELISA2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate.
AID38009Relative yield of the product (FPP) derived from the compound with DMAPP in the enzymatic reaction catalyzed by FPP synthase from avian liver1998Bioorganic & medicinal chemistry letters, Sep-22, Volume: 8, Issue:18
Substrate specificity of thermostable farnesyl diphosphate synthase with alkyl group homologs of isopentenyl diphosphate.
AID1346823Human mevalonate kinase (Lanosterol biosynthesis pathway)1997Journal of lipid research, Nov, Volume: 38, Issue:11
Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways.
AID1346567Mouse TRPA1 (Transient Receptor Potential channels)2010British journal of pharmacology, Oct, Volume: 161, Issue:3
Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (443)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (7.90)18.7374
1990's62 (14.00)18.2507
2000's168 (37.92)29.6817
2010's160 (36.12)24.3611
2020's18 (4.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.92 (24.57)
Research Supply Index6.13 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index70.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.44%)5.53%
Reviews48 (10.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other405 (89.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]